PMV Pharmaceuticals upgraded by Oppenheimer
$PMVP
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $6.00 | Perform → Outperform | Oppenheimer |
| 5/13/2024 | $6.00 | Buy | Craig Hallum |
| 4/12/2024 | $5.00 | Buy | Jefferies |
| 12/27/2023 | $7.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $30.00 | Perform → Outperform | Oppenheimer |
| 3/2/2022 | Perform → Outperform | Oppenheimer | |
| 9/22/2021 | $35.00 → $43.00 | Neutral → Buy | Goldman Sachs |
| 8/19/2021 | Perform | Oppenheimer |
SCHEDULE 13D/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
144 - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SCHEDULE 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months46% ORR observed among 48 evaluable patients in ovarian cancer cohort with a median duration of response of 8.0 monthsRezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 PRINCETON, N.J., Oct.
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that two abstracts have been accepted for oral and poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 202
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a median duration of response of 7.6 monthsRezatapopt New Drug Application submission for platinum resistant/refractory ovarian cancer planned in first quarter of 2027Company to host investor webinar at 8:00 AM ET today to review Phase 2 interim clinical data PRINCETON
Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform and set a new price target of $6.00
Craig Hallum initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $6.00
Jefferies initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $5.00
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Board. The Board changes are effective immediately. "We are thrilled to welcome Carol to our Board. She is a recognized industry leader with a stellar track record of creating value. Her capabilities in
Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021 CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights. "We expect that 2022 will be another pr
CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the appointment of Ms. Flowers, Peter Thompson, M.D. will resign from PMV's Board. "Peter has been an invaluable member of the Board during a period of substantial growth and key successes, including completion of our IPO as well as entry of our lead candidate, PC14586, into the clinic," said David Mack, Ph.D., President and Chief Executive Officer of PMV. "On behalf o